Insulet Corporation Announces Pricing of Secondary Public Offering

BEDFORD, Mass., Nov. 7 /PRNewswire-FirstCall/ -- Insulet Corporation, (Nasdaq: PODD), the manufacturer and marketer of the OmniPod(R) Insulin Management System, today announced the pricing of its public offering of 4,898,398 shares of common stock at $23.25 per share, all of which are being sold by selling stockholders. Insulet will not receive any proceeds from the sale of shares by the selling stockholders. Insulet has granted to the underwriters an option to purchase up to 734,759 shares of its common stock at the public offering price to cover any over-allotments.

J.P. Morgan Securities Inc. and Merrill Lynch, Pierce, Fenner & Smith Incorporated are acting as joint book-running managers, and Leerink Swann LLC, Thomas Weisel Partners LLC and Canaccord Adams Inc. are acting as co-managers for the offering.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission and has become effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offer or sale will be made only by means of the written prospectus forming part of the effective registration statement.

A copy of the prospectus relating to the offering may be obtained by contacting one of the following:

About Insulet Corporation

Insulet Corporation is an innovative medical device company dedicated to improving the lives of people with diabetes. The Company's OmniPod Insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use parts with no tubing and fully- automated cannula insertion. Through the OmniPod System, Insulet seeks to expand the use of continuous subcutaneous insulin infusion (CSII) therapy among people with insulin-dependent diabetes. Founded in 2000, Insulet is based in Bedford, MA.

For more information about Insulet Corporation and the OmniPod System, please visit our website at www.insulet.com.

SOURCE Insulet Corporation

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.